A GLP-1-free route to weight loss gains attention

A group of researchers behind GLP-1 obesity drugs propose an alternative: a high-dose molecule that activates GIP and glucagon receptors may achieve weight loss similar to GLP-1–targeting therapies, potentially with fewer side effects. The approach, funded by BlueWater Biosciences and described in Molecular Metabolism, is based on rodent and nonhuman primate data and has not yet been tested in humans, making findings uncertain and likely controversial for the field.